In this FFL, NFκB activates both CYLD, a tumor suppressor that inhibits the nuclear translocation of NFκB, and miR-19 which suppresses CYLD. If NFκB upregulates miR-19, relative to CYLD, this pathway ultimately allows for the sustained activation of NFκB in T-ALL through the miR-19 mediated inhibition of CYLD [14]. The gene discussed is NFKB1; the disease is acute lymphoblastic leukemia.